ClinicalTrials.gg
CompletedNCT04260464Updated Jan 22, 2024Results posted

Renal Impairment Study of PF-06700841

A Phase 1 interventional study of PF-06700841 in Healthy Volunteer and Renal Impairment, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
18th of 36
30 · median 30
Started
2020
with 1 other
Phase 1
23 of 37
2 open now
Registered
26th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2020, is one of 23 in phase 1, and was the 26th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.

Read the detailed description

This is a Phase 1 non-randomized, open-label, parallel cohort, multi-site study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of PF-06700841 after a single oral dose of 30 mg. Subjects will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. Part 1: A total of approximately 16 subjects will be enrolled; approximately 8 subjects with severe renal impairment and approximately 8 with normal renal function. After statistical evaluation of results from Part 1, Part 2 may be conducted with approximately 8 subjects each with moderate and mild renal impairment. The total duration of participation from Screening visit to Day 4 will be a maximum of 32 days and from Screening visit to Follow-up/Contact Visit will a maximum of 67 days.

03

Conditions studied

  • Healthy Volunteer
  • Renal Impairment

Browse trials for

Keywords

  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants who are between the ages of 18 and 75 years, inclusive, at the Screening visit.
  • (BMI) of ≥17.5 to ≤40 kg/m2; and a total body weight >50 kg.
  • Normal, Severe, Moderate and Mild renal function at 2 Screening visits.
  • Stable drug regimen

Exclusion criteria

Exclusion Criteria:

  • Renal transplant recipients.
  • Urinary incontinence without catheterization.
  • Subjects with infections within the past 6 months prior to first dose of study drug, evidence of active or chronic infection requiring oral treatment within 4 weeks prior to first dose
  • Known history of pulmonary embolism or recurrent deep vein thrombosis
  • Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    PF-06700841 Severe Renal Impairment

    This arm includes participants with severe renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1

    Drug: PF-06700841

  • Experimental
    PF-06700841 Normal Renal Function

    This arm includes participants with normal renal function who will receive a single oral dose of 30 mg PF-06700841 on Day 1

    Drug: PF-06700841

  • Experimental
    PF-06700841 Moderate Renal Impairment

    This arm includes participants with moderate renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1

    Drug: PF-06700841

  • Experimental
    PF-06700841 Mild Renal Impairment

    This arm includes participants with mild renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1

    Drug: PF-06700841

Interventions

  • A single dose of 30 mg PF-06700841 will be administered on Day 1

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

    Cmax is the maximum observed plasma concentration of PF-06700841 within 72 hours post dose, which was observed directly from the plasma concentration-time data.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose

  2. Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

    AUCinf was area under the concentration-time curve from time 0 to infinity, which was calculated for PF-06700841 from the concentration-time data.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose

  3. Cmax of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

    Cmax is the maximum observed plasma concentration of PF-06802530 (M1), a major metabolite of PF-06700841 within 72 hours post dose, which was observed directly from the plasma concentration-time data.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose

  4. AUCinf of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

    AUCinf was area under the concentration-time curve from time 0 to infinity, which was calculated for PF-06802530 (M1), a major metabolite of PF-06700841 from the concentration-time data.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Any events occurring following start of treatment or increasing in severity after the start of the treatment were counted as treatment emergent. An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect. Severe adverse events is an event that prevents normal everyday activities which is a category utilized for rating the intensity of an event.

    Time frame: From screening (Day-28 to Day -2) to up to 35 days after the study treatment (for a period of up to 63 days)

  2. Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

    The hematology, clinical chemistry and urinalysis abnormalities were summarized in accordance with the sponsor reporting standards without regard to baseline abnormality. Baseline is defined as the last planned predose measurement taken on Day -1.

    Time frame: Baseline (Day -1) and Day 4

  3. Number of Participants With Post-baseline Vital Sign Abnormalities

    Vital Signs were assessed against the criteria specified in the sponsor reporting standards for potential clinical concerns. Vital sign abnormalities criteria included: 1) Systolic blood pressure (BP) in millimeters of mercury (mmHg): \<90 mmHg with increase or decrease from baseline of ≥30 mmHg with high and low post baseline values; 2) Diastolic blood pressure (BP) (mmHg): \<50 mmHg with increase or decrease from baseline of ≥20 mmHg with high and low post baseline values; 3) Supine pulse rate in beats per minutes (bpm): \>120 or \<40 bpm. Categories with at least 1 participant having vital sign abnormality in any of the reporting arms, were reported in this outcome measure. Baseline is defined as the last planned predose measurement taken on Day 1.

    Time frame: Baseline (Day 1) and Day 4

  4. Number of Participants With Post-baseline Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria included: 1) QTc interval adjusted according to Bazett formula (QTcB) in millisecond (msec): \> 450, \>480, \>500, increase from baseline \>30, increase from baseline \>60; 2) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>30, increase from baseline \>60. Categories with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure. Baseline is defined as the last planned predose measurement taken on Day 1.

    Time frame: 0 hr pre-dose and 1-, 3-, and 6-hours post-dose on Day 1; Day 4

07

Results

Posted Jan 22, 2024

Participant flow

Healthy adult participants with normal renal function and adult participants with renal impairment were enrolled in this study.

Participant flow — Overall Study
MilestoneSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Started8778
Completed8778
Not completed0000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

Cmax is the maximum observed plasma concentration of PF-06700841 within 72 hours post dose, which was observed directly from the plasma concentration-time data.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
ng/mLSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function303.2 ± 34275.2 ± 27341.8 ± 17260.3 ± 89
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Test/reference ratio: 110.15 · 95% CI 83.76 to 144.86
  • Normal Renal Function vs Mild Renal Impairment · Test/reference ratio: 94.58 · 90% CI 55.84 to 160.19
  • Normal Renal Function vs Moderate Renal Impairment · Test/reference ratio: 124.20 · 90% CI 100.24 to 153.89
PrimaryArea Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

AUCinf was area under the concentration-time curve from time 0 to infinity, which was calculated for PF-06700841 from the concentration-time data.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
ng*hr/mLSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function2013 ± 571796 ± 772652 ± 751274 ± 199
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Test/reference ratio: 112.08 · 95% CI 60.85 to 206.45
  • Normal Renal Function vs Mild Renal Impairment · Test/reference ratio: 70.97 · 90% CI 27.60 to 182.49
  • Normal Renal Function vs Moderate Renal Impairment · Test/reference ratio: 147.70 · 90% CI 75.17 to 290.21
PrimaryCmax of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

Cmax is the maximum observed plasma concentration of PF-06802530 (M1), a major metabolite of PF-06700841 within 72 hours post dose, which was observed directly from the plasma concentration-time data.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose
Reported as:
Geometric mean · ng/mL
Cmax of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
ng/mLSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Cmax of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function250.4 ± 26141.0 ± 32172.1 ± 46187.1 ± 43
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Test/reference ratio: 177.53 · 95% CI 135.82 to 232.04
  • Normal Renal Function vs Mild Renal Impairment · Test/reference ratio: 132.69 · 90% CI 95.08 to 185.17
  • Normal Renal Function vs Moderate Renal Impairment · Test/reference ratio: 122.04 · 90% CI 84.47 to 176.30
PrimaryAUCinf of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

AUCinf was area under the concentration-time curve from time 0 to infinity, which was calculated for PF-06802530 (M1), a major metabolite of PF-06700841 from the concentration-time data.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours after dose
Reported as:
Geometric mean · ng*hr/mL
AUCinf of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
ng*hr/mLSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
AUCinf of PF-06802530 (M1) Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function7756 ± 411739 ± 243984 ± 152515 ± 32
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Test/reference ratio: 445.99 · 95% CI 326.55 to 609.13
  • Normal Renal Function vs Mild Renal Impairment · Test/reference ratio: 144.63 · 90% CI 112.76 to 185.50
  • Normal Renal Function vs Moderate Renal Impairment · Test/reference ratio: 229.12 · 90% CI 189.97 to 276.35
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Any events occurring following start of treatment or increasing in severity after the start of the treatment were counted as treatment emergent. An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect. Severe adverse events is an event that prevents normal everyday activities which is a category utilized for rating the intensity of an event.

Time frame:
From screening (Day-28 to Day -2) to up to 35 days after the study treatment (for a period of up to 63 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Participants with adverse events2013
Participants with serious adverse events0000
Participants with severe adverse events0000
Participants discontinued from study due to adverse events0000
SecondaryNumber of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

The hematology, clinical chemistry and urinalysis abnormalities were summarized in accordance with the sponsor reporting standards without regard to baseline abnormality. Baseline is defined as the last planned predose measurement taken on Day -1.

Time frame:
Baseline (Day -1) and Day 4
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
ParticipantsSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Hematology-Hemoglobin (HGB) (g/dL) <0.8✕lower limit of normal (LLN)2000
Hematology-Hematocrit (%) <0.8✕LLN1000
Hematology-Erythrocytes (10^6/mm^3) <0.8✕LLN1000
Hematology- Erythromycin (Ery.) Mean Corpuscular HGB (pg/cell) >1.1✕upper limit of normal (ULN)1000
Hematology-Ery. Mean Corpuscular HGB Concentration (g/dL) <0.9✕LLN0010
Hematology-Lymphocytes/Leukocytes (%) <0.8✕LLN1010
Hematology-Lymphocytes/Leukocytes (%) >1.2✕ULN0100
Hematology-Eosinophils/Leukocytes (%) >1.2✕ULN2000
Clinical chemistry-Blood Urea Nitrogen (mg/dL) >1.3✕ULN8020
Clinical chemistry-Creatinine (mg/dL) >1.3✕ULN8010
Clinical chemistry-Urate (mg/dL) > 1.2✕ULN5001
Clinical chemistry-Potassium (mEq/L) >1.1✕ULN0001
Clinical chemistry-Bicarbonate (mEq/L) <0.9✕LLN1000
Clinical chemistry-Glucose (mg/dL) >1.5✕ULN1042
Urinalysis-Urine Glucose ≥12011
Urinalysis-Urine Protein ≥12000
Urinalysis-Urine Hemoglobin ≥10001
Urinalysis-Urine Leukocyte Esterase ≥11102
SecondaryNumber of Participants With Post-baseline Vital Sign Abnormalities

Vital Signs were assessed against the criteria specified in the sponsor reporting standards for potential clinical concerns. Vital sign abnormalities criteria included: 1) Systolic blood pressure (BP) in millimeters of mercury (mmHg): \<90 mmHg with increase or decrease from baseline of ≥30 mmHg with high and low post baseline values; 2) Diastolic blood pressure (BP) (mmHg): \<50 mmHg with increase or decrease from baseline of ≥20 mmHg with high and low post baseline values; 3) Supine pulse rate in beats per minutes (bpm): \>120 or \<40 bpm. Categories with at least 1 participant having vital sign abnormality in any of the reporting arms, were reported in this outcome measure. Baseline is defined as the last planned predose measurement taken on Day 1.

Time frame:
Baseline (Day 1) and Day 4
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Vital Sign Abnormalities
ParticipantsSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
Number of Participants With Post-baseline Vital Sign Abnormalities0000
SecondaryNumber of Participants With Post-baseline Electrocardiogram (ECG) Abnormalities

ECG abnormalities criteria included: 1) QTc interval adjusted according to Bazett formula (QTcB) in millisecond (msec): \> 450, \>480, \>500, increase from baseline \>30, increase from baseline \>60; 2) QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>30, increase from baseline \>60. Categories with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure. Baseline is defined as the last planned predose measurement taken on Day 1.

Time frame:
0 hr pre-dose and 1-, 3-, and 6-hours post-dose on Day 1; Day 4
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Electrocardiogram (ECG) Abnormalities
ParticipantsSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
QTcB interval, single beat (msec): 450 < Value ≤ 4802013
QTcB interval, single beat (msec): 30 ≤ Change ≤ 600003
QTcF interval, single beat (msec): 450 < Value ≤ 4802110
QTcF interval, single beat (msec): 30 ≤ Change ≤ 600002

Adverse events

Collected over From screening (Day-28 to Day -2) to up to 35 days after the study treatment (for a period of up to 63 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Renal Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Normal Renal Function0/7 (0%)0/7 (0%)0/7 (0%)
Moderate Renal Impairment0/7 (0%)0/7 (0%)1/7 (14.3%)
Mild Renal Impairment0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventSevere Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal Impairment
NauseaGastrointestinal disorders1/80/71/70/8
Abdominal distensionGastrointestinal disorders0/80/70/71/8
DiverticulitisInfections and infestations0/80/70/71/8
Flank painMusculoskeletal and connective tissue disorders0/80/70/71/8
DizzinessNervous system disorders1/80/70/70/8
HeadacheNervous system disorders0/80/70/71/8

Baseline characteristics

All enrolled participants who were assigned to investigational product and took at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(Years)Severe Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal ImpairmentTotal
Mean (SD)65.9 ± 7.5762.4 ± 5.3868.4 ± 4.2461.5 ± 6.1664.5 ± 6.36
Age, Customized
Age, Customized(Participants)Severe Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal ImpairmentTotal
45-64 Years361616
>=65 Years516214
Sex: Female, Male
Sex: Female, Male(Participants)Severe Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal ImpairmentTotal
Female11248
Male765422
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Severe Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal ImpairmentTotal
White856827
Black or African American02103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Severe Renal ImpairmentNormal Renal FunctionModerate Renal ImpairmentMild Renal ImpairmentTotal
Hispanic or Latino442414
Not Hispanic or Latino435416
08

Study locations

3 sites
  • Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy
    Miami, Florida 33136, United States
  • University of Miami Division of Clinical Pharmacology
    Miami, Florida 33136, United States
  • Prism Research LLC dba Nucleus Network
    Saint Paul, Minnesota 55114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2022, 22 months.

Results were first posted in Jan 2024, 1 year 8 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 22 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2020
First posted
Feb 7, 2020
StartActual
Jul 3, 2020
Primary completionActual
May 4, 2022
CompletionActual
May 4, 2022
Results first posted
Jan 22, 2024
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04260464
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 7, 2020
Start date
Jul 3, 2020
Primary completion
May 4, 2022
Completion
May 4, 2022
Results posted
Jan 22, 2024
Last update
Jan 22, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion